269 related articles for article (PubMed ID: 29698666)
1. Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
Chang HL; Chen HA; Bamodu OA; Lee KF; Tzeng YM; Lee WH; Tsai JT
Toxicol In Vitro; 2018 Sep; 51():74-82. PubMed ID: 29698666
[TBL] [Abstract][Full Text] [Related]
2. Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways.
Huang YJ; Yang CK; Wei PL; Huynh TT; Whang-Peng J; Meng TC; Hsiao M; Tzeng YM; Wu AT; Yen Y
J Hematol Oncol; 2017 Feb; 10(1):60. PubMed ID: 28241877
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
Chen CL; Tsukamoto H; Liu JC; Kashiwabara C; Feldman D; Sher L; Dooley S; French SW; Mishra L; Petrovic L; Jeong JH; Machida K
J Clin Invest; 2013 Jul; 123(7):2832-49. PubMed ID: 23921128
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
Liu M; Bamodu OA; Kuo KT; Lee WH; Lin YK; Wu ATH; M H; Tzeng YM; Yeh CT; Tsai JT
Am J Chin Med; 2018; 46(4):891-910. PubMed ID: 29792038
[TBL] [Abstract][Full Text] [Related]
5. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
6. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
7. lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR‑375 sponging.
Zhao L; Lou G; Li A; Liu Y
Mol Med Rep; 2020 Aug; 22(2):1449-1457. PubMed ID: 32626943
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
[TBL] [Abstract][Full Text] [Related]
9. Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.
Chen MY; Hsu CH; Setiawan SA; Tzeng DTW; Ma HP; Ong JR; Chu YC; Hsieh MS; Wu ATH; Tzeng YM; Yeh CT
Phytomedicine; 2023 Jan; 108():154478. PubMed ID: 36265255
[TBL] [Abstract][Full Text] [Related]
10. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.
Lin Q; Wu Z; Yue X; Yu X; Wang Z; Song X; Xu L; He Y; Ge Y; Tan S; Wang T; Song H; Yuan D; Gong Y; Gao L; Liang X; Ma C
EBioMedicine; 2020 Mar; 53():102676. PubMed ID: 32114388
[TBL] [Abstract][Full Text] [Related]
11. YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells.
Bora-Singhal N; Nguyen J; Schaal C; Perumal D; Singh S; Coppola D; Chellappan S
Stem Cells; 2015 Jun; 33(6):1705-18. PubMed ID: 25754111
[TBL] [Abstract][Full Text] [Related]
12. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
13. LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells.
Zhu P; Wang Y; Wu J; Huang G; Liu B; Ye B; Du Y; Gao G; Tian Y; He L; Fan Z
Nat Commun; 2016 Dec; 7():13608. PubMed ID: 27905400
[TBL] [Abstract][Full Text] [Related]
14. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
Dai Y; Liu S; Zhang WQ; Yang YL; Hang P; Wang H; Cheng L; Hsu PC; Wang YC; Xu Z; Jablons DM; You L
Oncotarget; 2017 Jan; 8(3):4096-4109. PubMed ID: 27911857
[TBL] [Abstract][Full Text] [Related]
15. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
16. Furanocoumarin Notopterol: Inhibition of Hepatocellular Carcinogenesis through Suppression of Cancer Stemness Signaling and Induction of Oxidative Stress-Associated Cell Death.
Huang TY; Yang CK; Chen MY; Yadav VK; Fong IH; Yeh CT; Cherng YG
Nutrients; 2023 May; 15(11):. PubMed ID: 37299411
[TBL] [Abstract][Full Text] [Related]
17. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
Guo C; Wang X; Liang L
Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
[TBL] [Abstract][Full Text] [Related]
18. Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease.
Simile MM; Latte G; Demartis MI; Brozzetti S; Calvisi DF; Porcu A; Feo CF; Seddaiu MA; Daino L; Berasain C; Tomasi ML; Avila MA; Feo F; Pascale RM
Oncotarget; 2016 Aug; 7(31):49194-49216. PubMed ID: 27359056
[TBL] [Abstract][Full Text] [Related]
19. Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.
Quintavalle C; Hindupur SK; Quagliata L; Pallante P; Nigro C; Condorelli G; Andersen JB; Tagscherer KE; Roth W; Beguinot F; Heim MH; Ng CKY; Piscuoglio S; Matter MS
Cell Death Dis; 2017 Oct; 8(10):e3138. PubMed ID: 29072691
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma.
Kim GJ; Kim H; Park YN
PLoS One; 2013; 8(9):e75449. PubMed ID: 24086533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
